InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,214.08
(
0.51%
)
US TECH 100
17,644.40
(
0.24%
)
Dow Jones
39,387.76
(
0.85%
)
Brent Oil
84.00
(
0.52%
)
Bitcoin
62,505.03
(
2.14%
)
Post# of 146210
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

robi-1-kenobi

Send PM Follow Ignore
Followers 9
Posts 399
Boards Moderated 0
Alias Born 09/23/2013

robi-1-kenobi

Re: davidc2 post# 103034

Thursday, 10/30/2014 8:58:08 AM

Thursday, October 30, 2014 8:58:08 AM

Post# of 146210
You should actually read the PR. The difference is the EbolaCide2 ligands target a conserved portion of the Ebola virus that it needs to enter and infect the cells. The previous version's ligand targeted portions of the virus that it shed to fool the immune system. Likely to be a big difference in efficacy.
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent NNVC News
More NNVC News
InvestorsHub NewsWire

VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM

Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM

Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM

Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM

Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM

Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM

Start posting your company's news
Only $200 per official company press release!